MicroRNAs (miRNAs) are involved in the management of hematopoiesis. As a consequence, miRNA dysregulation causes disruption of the hematopoietic system and leukemia may arise. We here comprehensively discuss miRNAs found discriminative for cytogenetic and molecular subtypes of acute leukemia. These miRNAs are either known miRNAs involved in leukemogenesis with proven tumor suppressor or oncogenic activities or are newly identified by high-throughput sequencing with yet unknown function. Furthermore, forces are outlined that drive aberrant miRNA function, which include genetic abnormalities (for example, deletions, translocations and mutations) and epigenetic aberrations (for example, aberrant DNA methylation or histone modifications). Interestingly, leukemia-silenced miRNAs can be re-expressed upon treatment with de-methylating agents. Targeting miRNA expression may serve a therapeutical role, albeit at present this way of targeted therapy is in its infancy. However, emerging knowledge about the biology of miRNAs in leukemia may result into a role for these miRNAs in the diagnosis and treatment of acute leukemia.
In 1993, Ambros and Ruvkun discovered the first microRNA (miRNA) (lin-4) that repressed messenger RNA (mRNA) lin-14 through complementary base pairing in C. elegans.
1,2 It took till 2000 to recognize that this phenomenon was not restricted to worms, but also occurred in mammals. 3 Today miRNAs are known as highly conserved 18-25 nucleotides non-proteincoding small RNAs that regulate the expression of over 60% of all human genes. 4 MiRNAs achieve this regulation by binding with their seed sequence (usually covering nucleotide position 2-8 from the 5 0 miRNA) to a (partially) complementary sequence in the 3 0 untranslated region (3 0 UTR) of the targeted mRNA ( Figure 1 ). This leads to inhibition of translation or destabilization of the mRNA by deadenylation. 4 MiRNAs are processed from a larger stem-loop precursor (pre-miRNA) by the enzyme Dicer, generating double-stranded RNA (dsRNA) intermediates. One strand encodes the mature miRNA that forms a complex with Argonaute (Ago) proteins, which is mandatory for the miRNA in order to bind to its target-mRNA ( Figure 1 ). In contrast, the other strand (denoted as miRNA*-strand) is believed to be non-functional and is degraded upon its release. 5 The processing and final action of miRNAs shares similarities with RNA interference (RNAi). 6 This new pathway of translational regulation coincides with the discovery of miRNAs and was awarded with the Nobel Prize (2006) for its promise as therapeutic tool. 7 RNAi is triggered by exogenous dsRNA as part of a defense mechanism against viruses. Similar to endogenous miRNAs, dsRNAs are processed by Dicer and require binding to Ago proteins in order to silence genes. 6 Our understanding of miRNA functioning probably reflects a tip of the iceberg. MiRNA-mRNA base pairing may besides translational silencing also promote the expression of target genes. A pioneering study showed that miR-328 silences survival factor proviral integration site 1 (PIM1) through mRNA 3 0 UTR-base pairing and simultaneously interacted with the CCAAT/enhancer binding protein alpha (C/EBPa)-regulating protein, poly(rC)-binding protein hnRNP E2 in myeloid progenitor cells. 8 The interaction between miR-328 and hnRNP E2 was independent from the miRNA seed sequence, Dicer and Ago proteins and prevented hnRNP E2 from repressing C/EBPa translation. Although confirmatory studies are needed, these data imply that miRNAs can also regulate gene expression by interference with the function of regulatory translational factors. Other studies show that miRNA function is dependent upon the specific cell type. On one hand miR-221 and miR-222 function as tumor suppressors in erythroblastic leukemia cells, on the other hand the same miRNAs act as oncogenes in solid tumors. 9 All together, the dual abilities for miRNAs like the mRNA decay/ protein decoy activity for miR-328 ( Figure 1 ) and the dual function for miR-221/222 indicate that the role of miRNAs in diseases like acute leukemia may be more complex than previously appreciated.
MiRNA (mis)management of hematopoiesis
MiRNAs direct different biological processes including development, differentiation and hematopoiesis by regulating the expression of target genes. MiRNAs fine-tune the hematopoietic system and manage the control of both lymphoid and myeloid lineages. 10 Among others, miR-181 was one of the first miRNAs demonstrated to be preferentially expressed in hematopoietic tissue. Enforced expression in hematopoietic stem cells stimulated the differentiation into B-lineage cells. 11 MiR-328 stimulated differentiation of myeloid cells by promoting the expression of the master regulator of myeloid differentiation C/EBPa through scavenging of the translational inhibitor hnRNP E2. 8 Conversely, miR-124a prevents cells from differentiation toward the myeloid lineage via direct inhibition of C/EBPa protein expression. 12 The downregulation of miR-15a/16-1 because of a genomic deletion in chronic lymphocytic leukemia (CLL) patients provided the first link between disturbed miRNA expression and (hematopoietic) cancer. 13 Recently, it was
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confirmed that miR-15a/16-1-deletion contributes to the development of CLL. Mice with this deletion developed CLL or a related leukemia type, possibly by accelerating B-cell proliferation through regulating cell cycle-associated genes.
14 Enhanced B-cell proliferation was also observed in miR-155 transgenic mice, which finally developed acute lymphoblastic leukemia (ALL) and high-grade lymphoma. 15 Deletion of miR-145 and miR-146a genes on chromosome 5q was associated in patients with myelodysplastic syndrome. 16 Both miRNAs are abundantly expressed in normal hematopoietic stem/progenitor cells. Silencing of miR-145 and miR-146a in mouse hematopoietic stem/progenitor cells resulted into a myelodysplastic syndromelike phenotype, which progressed into a myeloid-like leukemia in mouse models. 16, 17 These studies exemplify that dysregulated expression of miRNAs may contribute to leukemogenesis by disturbing the tight control of normal hematopoietic processes.
Aberrant miRNA expression characterizes different cytogenetic and molecular subtypes in acute leukemia
To reveal, which miRNAs are dysregulated in acute leukemia, miRNA genome-wide expression studies have been conducted. These studies showed that leukemic cells of acute leukemia patients have different miRNA expression patterns than normal hematopoietic cells. [18] [19] [20] [21] Quantitative analysis of 397 miRNAs revealed that leukemic cells of pediatric precursor B-ALL patients have different miRNA expression profiles than samples of normal bone marrow and CD34 þ sorted cells. 22 Moreover, miRNAs were significantly differentially expressed between T-ALL cases and normal thymocytes. 22 Cytogenetically relevant types of ALL in children display characteristic miRNA expression signatures as visualized in Figure 2 (adapted from Schotte et al.
22
). Most striking differences were found for 11q23/ MLL-rearranged precursor B-ALL cases, which displayed downregulation of miR-708 and upregulation of miR-196b and t(12;21)/TEL-AML1-positive precursor B-ALL cases, which distinguished by upregulation of miR-383, miR-125b, miR-99a and miR-100 (Table 1) . 22 Remarkably, the miRNA signature of TEL-AML1-positive and hyperdiploid (450 chromosomes) ALL cases partly overlapped similar to what has been observed for mRNA expression profiles, 22, 29 which may suggest a common underlying biology. High expression of miR-33, miR-215, miR-369-5p, miR-496, miR-518d and miR-599 was associated with an unfavorable prognosis whereas high expression of other miR-genes (that is, miR-10a, miR-134, miR-214, miR-484, miR-572, miR-580, miR-624 and miR-627) was linked to a favorable prognosis in pediatric ALL. A combined profile of these 14 miR genes further improved the predictive value for long-term clinical outcome in children with ALL. 22 Adult acute myeloid leukemia (AML) patients with t(8;21)/ AML1-ETO or inv(16)/CBFb-MYH11 were distinguished from other AML patients by high and low expression of miR-126/126* (ref. 21) and let-7b/c, 20 respectively (Table 2) . High expression of another set of miRNAs including miR-382 was unique for t(15;17)/PML-RARa-positive AML. 18, 20 0 cap (m7G) binding with the initiation factor of translation eIF4E or by destabilizing the mRNA via deadenylation. If miR-328 binds to hnRNP E2, hnRNP E2 is prevented from inhibiting C/EBPa with translational re-activation of C/EBPa as a result. 8 Clinical relevance of miRNAs in acute leukemia D Schotte et al T-ALL Figure 2 Clustering of ALL subtypes by miRNA expression pattern. Subtypes of pediatric ALL cluster together based on similarities in miRNA expression patterns. The hierarchical clustering of cases is based on the expression level of miRNAs most discriminative for seven subtypes of ALL, as determined by stem-loop reverse transcriptase-quantitative PCR (for experimental details, see Schotte et al.
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). The 28 miRNAs represent the top 5 most discriminative miRNAs per subtype of which 2 miRNAs being discriminative for 41 subtype. The heatmap shows which miRNAs are overexpressed (in red) and which are underexpressed (in green) relative to snoRNA. Expression levels are plotted as standardized Z-scores per miRNA. Figure is adapted from data presented by Schotte et al.
Clinical relevance of miRNAs in acute leukemia D Schotte et al 3 MLL-rearranged AML cases, the oncogenic miR-17-92 cluster was upregulated 21, 34, 32 whereas the tumor-suppressor miR-29 was downregulated (Table 2) . 19, 23 MiRNA expression levels are also associated with molecular subtypes of AML, the mutational status and associated gene expression pattern in AML (Table 2) . Adult cases with cytogenetically normal (CN)-AML and favorable C/EBPa-mutations demonstrated higher levels of miR-181 (ref. 36) whereas CN-AML patients with unfavorable isocitrate dehydrogenase 2 (IDH2)-mutations displayed high levels of miR-1 and miR-133a 31 compared with CN-AML cases without these additional mutations. CN-AML patients with favorable nucleophosmin (NPM1)-mutations overexpressed several miRNAs including miR-10a, miR-10b, miR-100, miR-196a, miR-196b and let-7 whereas other miRNAs, that is, miR-126, miR-130a and miR-451 were downregulated compared with NPM1-wild-type cases. 30 Interestingly, NPM1-wild-type patients with relatively high expression of miR-126 often display increased transcription of the meningioma (MN1) gene, which is associated with an unfavorable prognosis. 37 The unique mRNA expression profiles associated with cytogenetic aberrations and mutational status of protein-coding genes and prognosis may reveal insight into the biology of these leukemia types.
Known miRNAs involved in leukemogenesis
Tumor suppressor miRNAs Let-7 is by far the most extensively studied miRNA and is known for its tumor suppressive capacities in a variety of malignancies by targeting different oncogenes including NRAS, KRAS, MYC and HMGA2, IMP1 and TRIM71. [38] [39] [40] [41] Besides in solid tumors, low levels of let-7b and let-7c were found in different types of acute leukemia for example, t(8;21) and inv(16)-positive adult AML (Table 2) . 20 Moreover, let-7b downregulation in children with MLL-rearranged ALL patients was linked to an upregulation of oncoprotein c-Myc suggesting that dysregulation of let-7 is not restricted to solid tumors but may also have a role in leukemia. Table 2 MiRNAs characterizing different cytogenetic and molecular subtypes in adult acute leukemia The expression of miR-29 is downregulated in MLL-rearranged AML and in NMP1-wild-type CN-AML (Tables 1 and 2) . 25 MiR-29 is known to inhibit genes involved in apoptosis (for example, MCL-1) 42 and cell cycling (for example, cyclindependent kinase 6 or CDK6).
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42 Luciferase 3 0 UTR-binding assays confirmed that miR-29b binds to MCL-1 mRNA. In correspondence, re-expression of miR-29b induced apoptosis by downregulating Mcl-1 expression in AML patient's samples and drastically reduced tumor growth in a leukemia xenograft model. 42 Another target of miR-29 (and miR-181) is the oncogene T-cell leukemia/lymphoma 1 (TCL1) in B-cell CLL (B-CLL). 43 Activation of this oncogene in transgenic mice led to development of CD5 þ leukemia resembling B-CLL in humans. 44 This mouse model was built with only the proteincoding part of the TCL1 gene. Another model by Efanov et al. 45 comprised the total length of TCL1 gene including the 3 0 UTR that contains binding sites for miR-29 (and miR-181). The fulllength TCL1 transgenic mice developed leukemia with delayed onset compared with the model lacking the 3 0 UTR. 44 These findings suggest that negative regulation of TCL1 by miR-29 and miR-181 inhibit the progression of B-CLL disease and supports a role for miR-29 as tumor suppressor gene in leukemia. Whether, however, dysregulation of TCL1 contributes to acute leukemias is yet unknown.
Oncogenic miRNAs
The high expression of miR-126/miR-126* in inv(16) and t(8;21)-positive AML patients (Table 2) prompted Li et al. 21 to functionally study these miRNAs. Enforced expression of miR-126 and its star strand in AML cell lines inhibited the apoptotic potential and facilitated cell survival. In addition, proliferation of mouse bone marrow progenitors was preferentially enhanced by enforced expression of miR-126 in combination with the t(8;21) fusion. 21 Therefore, miR-126/126* is considered as oncogene to be involved in leukemogenesis of t(8;21) AML.
MiR-24 is another miRNA activated in t(8;21)-positive AML patients (Table 2) . 35 Its upregulation is caused by binding of the AML-ETO fusion product to the miR-24-23-27 gene locus. 35 MiR-24 inhibits the synthesis of mitogen-activated protein kinase phosphatase 7, thereby facilitating cell growth through activation of c-jun and p38 kinases in myeloid leukemia cells. 35 MiR-125b and neighboring miRNA genes let-7c, miR-99a and miR-100 were aberrantly upregulated in TEL-AML1-positive ALL and different myeloid leukemias (Tables 1 and 2) . 24, 46, 47 Pro-B cells gained a survival advantage 24 and differentiation of CD34 þ myeloid progenitors was disturbed upon miR-125b overexpression. 46, 47 Moreover, the oncogenic activity of miR-125b was recently shown in mice, which were transplanted with fetal liver cells that overexpressed miR-125b. 48 These xenografted mice developed B-ALL and T-ALL suggesting an active role for miR-125b in leukemogenesis. 48 Furthermore, overexpression of miR-125b in BCR-ABL-positive leukemia cells accelerated the development of leukemia suggesting that miR-125b facilitates the oncogenic action of the BCR-ABL fusion gene. 48 A potential pathway involved in miR-125b-facilitated-leukemogenesis may include the downregulation of IRF4, a transcription factor that inhibits proto-oncogene BCL-6 (B-cell CLL/lymphoma 6) in lymphoma. 49 Enforced expression of miR-125b also facilitated IL3-independent growth of Ba/F3 mouse cells. 24 In addition to its oncogenic role, miR-125b expression has been associated with drug resistance in TEL-AML1-positive pediatric ALL. 22 Functional studies showed that inhibition of miR-125b sensitized TEL-AML1-positive cells to doxorubicin. 24 These studies exemplify a role for miR-125b in leukemogenesis and points to miR-125b as potential therapeutic target. MiR-155 is overexpressed in lymphomas, FLT3/ITD þ AML and different pediatric ALL subtypes. 23, 25, [50] [51] [52] [53] MiR-155 acts as an oncogene as its introduction in mouse bone marrow resulted in myeloproliferative disorders 54 and B-lineage ALL/lymphoma. 55 The oncogenic effect was mediated by downregulation of SHIP (Src homology 2 domain-containing inositol-5-phosphatase) and C/EBPb. 15 Both genes were predicted by TargetScan (www.targetscan.org) and subsequent luciferase 3 0 UTR-binding assays confirmed the binding of miR-155. 15 Transduction of miR-155 in natural killer-cell lymphoma/leukemia led apart from the downregulation of SHIP also to the inhibition of the tumorsuppressor genes PTEN (phosphatase and tensin homologue) and PDCD4 (programmed cell death 4). 53 As SHIP and PTEN are both negative regulators of the PI(3)K survival pathway this in turn resulted in upregulated phosphorylated Akt thereby rescuing cells from apoptosis and boosting proliferation. 53 Initially, miR-21 was found overexpressed in different types of tumors including leukemia and lymphoma. 56 Overexpression of miR-21 in transgenic mice caused precursor B-cell lymphoblastic leukemia/lymphoma. 56 These lymphoid malignancies disappeared by induction of apoptosis and proliferation arrest upon silencing of miR-21. This shows that miR-21 itself is capable to initiate, maintain and support survival of lymphoma/ leukemia in vivo.
56
Upregulation of miR-196b coincides with HOXA overexpression in pediatric MLL-rearranged precursor B-ALL, HOXAactivated T-ALL 57 and in different subtypes of AML 20, 23, 30 ( Tables 1 and 2 ). The high level expression of miR-196b was not predictive for prednisolone resistance in pediatric ALL, albeit MLL-rearranged cases are more resistant to this drug.
57,58
Overexpression of miR-196b facilitated proliferation and blocked differentiation in mouse bone marrow progenitor cells, 59 which may be indicative for a role in leukemogenesis. In contrast to promoting leukemogenesis, miR-196b may also inhibit this process as miR-196b and miR-196a were recently reported to downregulate the oncogenic transcription factor ERG in adult patients with AML and T-ALL. 60 Like discussed for miR-221/222, miR-196a/b may therefore have a dual role in leukemia depending on the genetic context of cells.
The miR-17-92 cluster located on chromosome 13q31 consists of six miRNAs, that is, miR-17/17*, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a, and was found overexpressed in MLL-rearranged acute leukemias and T-ALL patients (Table 2) . 20, 21, [32] [33] [34] 61 Together with the fact that this polycistronic cluster cooperated with c-Myc to accelerate B-cell lymphoma formation in vivo 62 suggests that miR-17-92 acts as an oncogene in lymphoid tissue. Induced expression of the miRNA cluster enhanced the colony-forming capacity of mouse bone marrow progenitors especially when MLL fusion genes were co-expressed. 32, 61 Increased expression of the miR-17-92 cluster was associated with a downregulation of p21 inhibitor of cell cycle progression. Complete knockdown of p21 mimicked the oncogenic effect of miR-17-92 in MLL-rearranged leukemia cells. 61 p21 and 19 other genes are predicted targets for miR-17-92 by TargetScan (www.targetscan.org), PicTar (http://pictar. mdc-berlin.de), MAMI (http://mami.med.harvard.edu) and/or Miranda (www.microRNA.org). 34 These potential target genes were all downregulated in MLL-rearranged ALL. 32, 34, 61 Two genes, that is, APP and RASSF2 were confirmed targets for miR-17-92 as shown by a luciferase 3 0 UTR-binding assay 34 and the expression of one gene (that is, TNFRSF21) inversely correlated with the expression of the miR-17-92 cluster. 32 The miR-17-92 cluster also has a oncogenic role in T-ALL. Mice transplanted
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Clinical relevance of miRNAs in acute leukemia D Schotte et al 5 with miR-19/Notch1-overexpressing hematopoietic progenitor cells developed ALL faster than mice receiving progenitor cells transfected with Notch1. 33 To identify the target genes of miR-19, a large-scale short hairpin screen was performed. 33 About 14 000 shRNAs were transduced into a cell line model to search for genes whose silencing resembled the proliferative effect of miR-19. Four human genes were identified that harbored miR-19-binding sites in their 3 0 UTR, that is, proapoptotic Bim (BCL2L11), tumor-suppressor PTEN, AMP-activated kinase (PRKAA1), phosphatase PP2A (PPP2r5e) and dedicator of cytokinesis-5 (DOCK5). Except for DOCK5 all identified target genes were confirmed by luciferase 3 0 UTR-binding assays and other functional studies using miR-19-overexpression and inhibition strategies. These protein-coding genes represent known negative regulators of the phosphatidylinositol-3-kinase (PI(3)K) survival pathway and silencing of these genes largely affected lymphocyte survival in vitro and accelerated leukemogenesis in Notch1-induced T-ALL in vivo. 33 This suggests that coordinated knockdown of these survival inhibitors is responsible for the oncogenic effect of miR-19 in Notch1-induced T-ALL.
Novel miRNAs potentially involved in leukemogenesis
The major disadvantage of miRNA profiling studies is that they are focused on known miRNAs. As miRNA function and expression is highly dependent upon its cellular context and most miRNAs have been discovered in non-leukemic tissue, profiling studies may have missed miRNAs important to acute leukemia and its subtypes. For this reason we and others cloned miRNAs from patient's leukemia cells. 26, 28, [63] [64] [65] Initially, a small RNA concatemer-cloning procedure was used followed by Sanger sequencing and bio-informatic analysis. 26, 63 This led to the identification of eight novel miR-genes in MLL-and non-MLL rearranged ALL. 26 With the more sensitive high-throughput sequencing or deep sequencing method another set of 28 novel and 431 candidate novel miR-genes were identified in 7 subtypes of ALL. 28 Stem-loop quantitative reverse transcriptase-PCR demonstrated that these novel and candidate novel miRNAs were differentially expressed between different cytogenetic subtypes of ALL and between ALL and normal hematopoietic cells. 28 In total, 186 novel (candidate) mature miRNAs and miRNA*-strands were found exclusively in ALL subtypes whereas 84 were found uniquely expressed in normal hematopoietic cells. 28 High-throughput sequencing of 3 pediatric ALL cases and 2 normal bone marrow samples by Zhang et al. 65 revealed 42 novel miRNAs of which 5 were unique to ALL and 22 exclusively detected in normal donor bone marrow cells. The differential expression of these newly identified miRNAs between leukemic cells and normal hematopoietic cells warrants further studies for their potential role in leukemogenesis.
Forces that drive the dysregulation of miRNAs in acute leukemia
MiRNA dysregulation may be due to genomic aberrations including amplifications and translocations, especially because many miRNAs are encoded on such fragile sites. For example, amplification of the miR-17-92 gene cluster contributed to the high level of expression of this cluster in MLL-rearranged patients. 32 In addition, MLL-fusion proteins 32, 61 and oncogene c-myc may be responsible for miR-17-92 cluster overexpression. 61 In T-ALL, the newly identified translocation t(13;14)(q32;q11) targeted the miR-17-92 gene cluster and possibly thereby facilitates its expression. 33 Moreover this rearrangement coincided with an activating Notch1 translocation that is, t(9;14)(q14;q11), 33 which even more supports the activation of the cluster because Notch1 can target c-Myc, the direct regulator of miR-17-92. 61, 66 Interestingly, miR-494 and miR-320a were downregulated by the TEL-AML1 fusion protein derived from the t(12;21)/(p13;q22) translocation found in B25% of children with ALL (Table 1) . 27 As both miRNAs were shown to target the anti-apoptosis protein survivin this may facilitate the survival and proliferation of TEL-AML1-positive ALL cells. 27 Also genomic deletions may dysregulate the expression of miRNAs. The chromosome 13q14 deletion is responsible for the inactivation of miR-15/16-cluster in CLL patients 13 and a deletion of 7 Mb on chromosome 12 reduced the expression of miR-203 in murine T-cell leukemias/lymphomas. 67 MiR-128b sensitizes MLL-rearranged leukemia cells to prednisone 68 and a mutation in the miR-128b gene reduced the amount of mature miR-128b leading to prednisone resistance. 69 The occurrence of the mutation in miR-128b may indicate that other mutations exist, which drive leukemogenesis and/or response to treatment. Recent studies show that mutations in pseudogenes may affect the expression of other genes by alternative scavenging of miRNAs. 70 For example, pseudogene PTENP1 acts as decoy for PTEN-targeting miRNAs as both PTENP1 and PTEN share a highly similar 3 0 UTR. 70 Copy number losses and mutations affecting the binding of miRNAs to 3 0 UTR of PTENP1 were found that may be responsible for the downregulation of the tumor-suppressor gene PTEN in leukemia. 33, 70 Apart from genomic aberrations or aberrant activity of specific regulatory factors (for example, c-Myc), miRNA dysregulation may also be caused by aberrant expression of neighboring protein-coding genes. For example, miR-196b is co-expressed with its neighboring genes HOXA9 and HOXA10 in MLL-rearranged ALL, 57 T-ALL 57 and AML patients. 23 Similar co-activation may explain the high association for miR-10a (positioned in between HOXB4 and HOXB5) as well as miR-196a (encoded in between HOXB9 and HOXB13) with the HOXB cluster as observed in adult 25, 71 and childhood AML. 23 It is, however, intriguing that aberrant expression of neighboring genes, genomic aberrations and specific regulatory factors can only explain the minority of dysregulated miRNAs whereas an explanation is still lacking for the majority of aberrantly expressed miRNAs in acute leukemia.
MiRNAs as bystanders and actors of epigenetics
A deletion of miR-203 affects one allele and is often accompanied by CpG hypermethylation of the second allele in mice. 67 This results in the complete silencing of miR-203 in mice. Silencing of miR-203 was also found in human T-cell leukemias and illustrates that modification by epigenetics can be another regulatory level of miRNA expression. The genetic and epigenetic silencing of miR-203 is of clinical relevance because this miRNA controls the expression of the oncogene c-ABL and BCR-ABL fusion product in the prognostically unfavorable group of t(9;22)/BCR-ABL1-translocated precursor B-ALL and chronic myeloid leukemia. 67 The epigenetic regulation of miRNA expression may be a bystander effect of the epigenetic control on protein-coding genes. The locus of the precursor of miR-126/miR-126* is embedded in a 287-bp CpG island and the high expression of 21 Similarly, high expression of miR-196b involved in leukemogenesis was associated with CpG island hypomethylation of the promoter region of the miR-196b/HOXA locus in MLL-rearranged ALL, which is on itself remarkable because MLL-rearranged ALL is characterized by genome-wide CpG island hypermethylation. 57, 72 The MLL fusion product, however, may be directly involved in the mechanism underlying the transcriptional activation of the miR-196b/HOXA locus as it has been demonstrated that this fusion product recruits DOT1L histone methyltransferase leading to dimethylation of histone H3 lysine 79 residues (H3K79me2). This H3K79 dimethylation allows further chromatin remodelling and opens up the entire HOXA cluster including the embedded miR-196b gene. 73 The hypomethylation of miR-196b/HOXA locus is MLL-specific because in other non-MLL precursor B-ALL a closed chromatin structure was observed with concomitantly hypermethylation of miR-196b/HOXA locus and reduced expression of these genes. 57 The regulation of gene expression by epigenetics also involves modifications of histones by methylation (for example, H3K79me2) and acetylation (for example, H3K56 acetylation). 74 The effect of the histone deacetylase inhibitor, trichostatin A was studied in an ALL cell line. 75 Trichostatin affected the expression of 440 miRNAs including miR-22. MiR-22 was re-expressed upon reduction of H3K27 trimethylation of histones in close proximity of its promoter area, whereas DNA methylation was not affected. This illustrates that histone modifications can, independently from DNA methylation, contribute to regulation of miRNA expression in ALL. In addition, ChIP-on-Chip analyses of 27 800 CpG islands in two ALL cell lines revealed that miR-124a and 11 other miR-genes displayed both aberrant DNA methylation and histone modifications that resulted into a closed chromatin structure. 76, 77 These epigenetic events contributed to the transcriptional silencing of miR-124a, which in turn accelerated growth of ALL cells via upregulation of target CDK6 and phosphorylation of retinoblastoma. 76 Besides the fact that expression of miRNAs can be regulated by DNA methylation and histone modifications, miRNAs themselves can regulate the transcription of genes involved in the epigenetic machinery. Tumor suppressor miR-29b targets the DNA methyltransferases DNMT1 and DNMT3, which facilitate maintenance and de novo DNA methylation, respectively. 78 Enforced expression of miR-29b led to global DNA hypomethylation and re-expression of the tumor-suppressor genes p15
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INK4B and estrogen receptor 1 in AML. 78 Recently, we proposed that miR-152 may be another actor of the epigenetic machinery because the seed sequence of miR-152 shared sequence homology with the 3 0 UTR of the DNMT1 transcript and expression levels of miR-152 inversely correlated to those of DNMT1 in MLL-rearranged ALL. 79 Others have added miR-290 to this list of so-called 'epi-miRNAs' upon the finding that miR-290 controlled DNA methylation and telomere recombination through retinoblastoma-like 2-dependent regulation of DNMTs. 80 Interestingly, a recent report demonstrated the discovery of a new class of miRNAs that directly (independent of target genes) mediated DNA methylation in plants. 81 After their loading into AGO4 clade proteins, these 24 nucleotide long miRNAs (lmiRNAs) directed DNA methylation at their own loci in cis as well as at their target genes in trans resulting a downregulation of target genes, likely via recruitment of de novo cytosine methyltransferase DRM2. 81 This fits in the hypothesis that Dicer processed miRNAs are required to maintain DNA methylation in human cancer cells. 82 In summary, miRNAs may function both as bystander and as actor of the epigenetic control of gene expression.
miRNAs as therapeutical tool
Using epigenetic drugs
The actors of the epigenetic machinery are themselves under epigenetic control and therefore deregulated expression may be restored by epigenetic drugs. Treatment of ALL cells with trichostatin A resulted in re-expression of miR-124a by opening the chromatin structure via reduction of H3K27 trimethylation. 75 A similar result was established by 5-aza-2 0 -deoxycytidine that demethylated the promoter of miR-124a. 76 Patients may benefit from restoring miRNAs back to normal levels, especially because hypermethylation of miR-124a was linked to a higher relapse and mortality rate in ALL patients. 76 Despite the favorable effect of miR-124a re-expression in precursor B-ALL, the effect of treatment in AML is less clear. In AML, both miR124a and its target gene C/EBPa are hypermethylated. 12 Consequently, reactivation of miR-124a not only executes a tumor-suppressive effect by downregulating CDK6 but also prevents demethylated C/EBPa of being restored to normal levels.
12 C/EBPa is crucial for myeloid but not lymphoid differentiation and its low levels may contribute to the differentiation block underlying AML. Therefore, ALL patients may benefit more from miR-124 re-activation upon epigenetic drugs than AML patients.
Exposure to the de-methylating drug zebularine re-activated seven out of 11 miR-genes that were downregulated in children with t(4;11)-positive MLL-rearranged ALL because of CpG island hypermethylation. This is illustrated for miR-152 in Figure 3 (adapted from Stumpel/Schotte et al. 79 ). The silencing by DNA methylation suggests that miR-152 and the other six miRNAs (that is, miR-200b, miR-200a, miR-429, miR-503, miR-432 and miR-10a) have tumor suppressive capacities similar to miR124a. Accordingly, miR-432 is part of the large miR-127 tumor suppressor cluster that downregulates protein levels of BCL-6.
79
In addition, re-expression of miR-200b coincided with downregulation of the oncogene ZEB2, which is highly expressed in t(4;11)/AF4-MLL-positive ALL 79, 83 and led to disease progression in human cancer. 84 MLL wild-type, AF4-MLL and DNMT1 were identified as potential target genes for miR-152 based on 3 0 UTR sequence homology. 79 This is of high interest because the co-expression of MLL wild-type is facilitating MLL-AF9-induced leukemogenesis 85 and the AF4-MLL reciprocal fusion protein contributes to leukemic transformation. 86 Moreover high levels of DNMT1 may be responsible for the genome-wide hypermethylation that characterizes t(4;11)/AF4-MLL-positive ALL and was linked to an increased risk of relapse. 72 None of the reactivated miRNAs was associated with DNA hypermethylation in adult or pediatric non-MLL precursor B-ALL. Their hypermethylation-related reduced expression levels are therefore specific for MLL-rearranged ALL. The degree of methylation of miR-152 was also predictive for a poor clinical outcome of MLLrearranged ALL, 79 which points to the potential of de-methylating drugs as new therapeutic agents to treat this type of pediatric ALL. Treatment with a miR-196b-specific antagomir abrogated the growth advantage of MLL-AF9 transformed/miR-196b overexpressing bone marrow cells 59 suggesting that inhibition of even a single miRNA may provide significant therapeutic benefit. Interestingly, the effectivity of antagomirs is not limited to the in vitro situation. Intravenous administration of antagomirs directed against miR-16, miR-122, miR-192 and miR-194 resulted in specific and long-lasting reduction of miRNA levels in mice. 87 In addition, intravenous injections with locked nucleic acid-anti-miR-122 formed stable heteroduplexes with liver-specific miR-122 leading to its depletion from liver in nonhuman primates. 88 As miR-122 is essential for the hepatitis C virus, 89 the locked nucleic acid-anti-miR-122 is currently being explored as therapeutical tool for this disease as part of a worldwide clinical trial. 90 Anti-miRNA molecules are thus promising silencers of miRNAs. Hence, their effectivity to treat acute leukemia deserves further study.
Using non-epigenetic drugs
In addition to the direct downregulation by anti-miRNA molecules, one could also consider the use of miR-masks 91 and miRNA sponges. 92 MiR-masks are usually 2 0 -O-methyl-modified oligoribonucleotides of 22-nucleotide length that compete with endogenous miRNA by blocking the complementary 3 0 UTRbinding site of its target mRNA. 91 The disadvantage of miRmasks is that they affect the expression of one target gene, whereas molecules that directly target a miRNA will affect all (multiple) targets of that specific miRNA. 91 As an alternative, miRNA sponges may be used. MiRNA sponges are short oligonucleotide sequences that contain multiple miRNA binding sites to which target miRNAs can bind. This reduces the number of free miRNA molecules that can bind to their (multiple) biological target mRNAs. 93 The sponges can be introduced into cells by adenoviral and lentiviral viruses in mice. 92 A lentiviral miR-326 sponge was delivered via intravenous injection in mice with experimental autoimmune encephalomyelitis and this resulted in the depletion of miR-326 in CD4 þ T cells. 94 As a consequence, the miRNA sponge reduced the development of the autoimmune disease in these mice. 94 The advantage of miRNA sponges over direct anti-miRNA molecules is that they can inhibit function of a complete miRNA family with similar seed sequence. On the other hand, their delivery needs a viral vehicle and requires integration in the host genome, which makes the therapeutic controlling and dosing in patients more difficult than in case of anti-miRNA molecules.
On one hand miRNAs may be targeted by therapeutic agents, on the other hand miRNAs themselves may serve as 'targeted drug', especially those with tumor suppressive function. A variety of functional studies have overexpressed specific (precursor) miRNAs in cells of different origin, either via synthetic molecules or viral vectors, in order to study reactivation of tumor suppressive miRNAs that are lost during leukemia development. Tissue-specific expression requires a retroviral or adenoviral vector with a tissue-specific promoter. This approach led to high level of miR-26a expression in liver and dramatically inhibited local tumor formation. 95 A similar strategy may be used to target leukemia cells, for example, by using the LCK-promoter to drive miRNA expression in T-ALL.
Challenges for miRNA-redirected treatment
Before using these manipulators of miRNA function in leukemia patients a few hurdles have to be taken. Administration of anti-miRNA molecules may have off-target effects on miRNAs to Clinical relevance of miRNAs in acute leukemia D Schotte et al 8 which they have a partial complementarity. 96 At first glance, off-target effects may be more manageable in case of (re)-introducing a (precursor) miRNA that is normally present in healthy non-leukemic cells. Unfortunately, this ectopically introduced miRNA may overload the RNA-induced silencing complex thereby affecting the processing of other miRNAs necessary for the survival of healthy (non-leukemic) cells. 97 Moreover, viral delivery of miRNAs may potentially activate the immune system. 98 Although the off-target toxicity associated with miRNA-specific replacement and depletion strategies is reported to be low, 9 further research should first elucidate potential off-target effects before implementation in clinics.
The main challenge to overcome before applying miRNArelated drugs in the clinic is the delivery of these drugs to the affected tissue, for example, bone marrow in acute leukemia. As mentioned above a viral vector with a tissue-specific promoter may be used. Synthetic miRNA mimics or anti-miRNA molecules do not have this benefit. Alternatively, aptamers (RNA oligonucleotides fused to the (anti-) miRNA) and liposomes may be used. 96 Aptamers and liposomal particles can direct the attached (anti)-miRNA molecule to specific cell surface receptors. As aptamers have only recently been discovered, liposomal particles have undergone more study so far. Liposomes direct the delivery of miRNAs to specific organs through modifications added to the liposomal surface. 98 Theoretically, such modifications like immunoconjugates directed against CD19 and CD33 could be applied in treatment of (precursor)-B-ALL and AML, respectively. 98 Moreover, the lipid coating itself increases the size of the miRNA or anti-miRNA particle and increases the half-life of the molecule because of reduced renal clearance. Antagomirs are examples of antimiRNA molecules that make use of the lipid coating as they have a cholesterol moiety at their 3 0 end. Antagomirs also have 2 0 O-methyl modifications for stability and a phosphorothioate backbone in order to make them resistant to exonuclease cleavage thereby increasing the half-life of the antagomir. 96, 98 An example of a lipid-coated synthetic miRNA molecule is miR-34. 97 This miRNA mimic was intravenously delivered in mice with lung tumors and blocked growth of these tumors. 97 Moreover, its systemical delivery did not induce an immune system response or elevation of liver or kidney enzymes and was thus well tolerated. The uptake of synthetic miR-34 by normal cells had no effect as the affected pathways were already activated by the endogenous miRNAs in these cells. 97 
Conclusions and future perspectives: biological players becoming clinical contributors
The discovery of miRNAs as powerful regulators of gene expression shed a new light on our understanding of acute leukemia. It became evident that leukemia is not only a disease of dysregulated protein-coding genes. In contrast, the biology of acute leukemia involves also dysregulation of the regulators of these genes, that is, miRNAs. Accordingly a number of miRNAs have been reported that serve a tumor suppressive and/or oncogenic role in acute leukemia (Tables 1 and 2 ). Unique miRNA expression patterns were found for different genetic, prognostic, mutational and drug-resistant subtypes of acute leukemia. This implies that miRNAs have potential to classify patients and that specific subtypes may benefit from treatment strategies opposing the gain of oncogenic or loss of tumor suppressor function of miRNAs.
Besides being bystanders of epigenetics, miRNAs themselves act as epigenetic factors, which make the consequences of their aberrant expression far more complex. Epigenetic drugs like DNA de-methylating agents and histone modifiers can reverse epigenetic changes and re-activate silenced miRNA. Therefore, these drugs deserve further exploration in patients, particularly because the methylation degree of several miR-genes correlated to clinical outcome in acute leukemia. Direct manipulation of miRNA expression by anti-miRNA molecules or tissue-directed viral delivery is also a promising therapeutic option when safety has been proven.
In conclusion, miRNAs were discovered as small biological players but despite their small size their impact on diseases like acute leukemia seems to grow with every miRNA-related publication. Aberrant expression and function of oncogenic and tumor suppressive miRNAs may contribute to the biology of diverse leukemia subtypes. We are beginning to understand their clinical impact step by step since recent studies showed that expression and methylation levels are linked to clinical outcome and patients may thus benefit from miRNA-targeted therapeutic strategies. Therefore, these small biological players may become clinical contributors in the diagnosis and treatment of acute leukemia.
